SGLT-2 Inhibitors (e.g., canagliflozin, dapagliflozin): These medications help eliminate glucose through urine, offering a viable alternative for those who cannot tolerate GLP-1 receptor agonists
Conclusion: This meta-analysis of RCTs provides reassuring evidence that GLP-1 receptor agonists were not associated with an increased risk of gastrointestinal cancers, with signals suggesting a possible reduction in colorectal and liver cancer incidence that should be interpreted cautiously
We understand how difficult dieting and exercise can be in the 21st century, so modern times call for modern solutions
Some of these compounds are FDA-approved, many are not
If nausea is significantly affecting your quality of life, do not simply stop your medication without speaking to your GP or prescriber first, as abrupt discontinuation may not be necessary and alternatives may be available
(2023) Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and metaanalysis including the 2year STEP 5 trial